HealthEquity Net Income From Continuing Ops from 2010 to 2024

HQY Stock  USD 103.57  0.19  0.18%   
HealthEquity Net Income From Continuing Ops yearly trend continues to be fairly stable with very little volatility. Net Income From Continuing Ops is likely to outpace its year average in 2024. During the period from 2010 to 2024, HealthEquity Net Income From Continuing Ops regression line of annual values had r-squared of  0.02 and arithmetic mean of  20,490,373. View All Fundamentals
 
Net Income From Continuing Ops  
First Reported
2012-04-30
Previous Quarter
28.8 M
Current Value
35.8 M
Quarterly Volatility
15.1 M
 
Yuan Drop
 
Covid
Check HealthEquity financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HealthEquity's main balance sheet or income statement drivers, such as Depreciation And Amortization of 160.7 M, Interest Expense of 58.2 M or Selling General Administrative of 108.8 M, as well as many indicators such as Price To Sales Ratio of 6.57, Dividend Yield of 0.0735 or PTB Ratio of 5.64. HealthEquity financial statements analysis is a perfect complement when working with HealthEquity Valuation or Volatility modules.
  
Check out the analysis of HealthEquity Correlation against competitors.
For more information on how to buy HealthEquity Stock please use our How to Invest in HealthEquity guide.

Latest HealthEquity's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of HealthEquity over the last few years. It is HealthEquity's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HealthEquity's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Pretty Stable
   Net Income From Continuing Ops   
       Timeline  

HealthEquity Net Income From Continuing Ops Regression Statistics

Arithmetic Mean20,490,373
Geometric Mean22,708,296
Coefficient Of Variation152.76
Mean Deviation23,809,115
Median10,166,000
Standard Deviation31,301,362
Sample Variance979.8T
Range118.2M
R-Value0.15
Mean Square Error1030.1T
R-Squared0.02
Significance0.58
Slope1,078,076
Total Sum of Squares13716.9T

HealthEquity Net Income From Continuing Ops History

202458.5 M
202355.7 M
2022-26.1 M
2021-44.3 M
20208.8 M
201939.7 M
201873.9 M

About HealthEquity Financial Statements

HealthEquity investors use historical fundamental indicators, such as HealthEquity's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in HealthEquity. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income From Continuing Ops55.7 M58.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for HealthEquity Stock Analysis

When running HealthEquity's price analysis, check to measure HealthEquity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HealthEquity is operating at the current time. Most of HealthEquity's value examination focuses on studying past and present price action to predict the probability of HealthEquity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HealthEquity's price. Additionally, you may evaluate how the addition of HealthEquity to your portfolios can decrease your overall portfolio volatility.